New game
Download
Get Academic Plan
Share game
Fill in the Blanks
Fill in the Blanks

bio med and cml treatment

Integrate it into your platform

You can integrate the game into an LMS compatible with LTI 1.1 or LTI 1.3 such as Canvas, Moodle, or Blackboard. This way, the scores will be automatically saved into the platform’s gradebook.
Download
You have exceeded the maximum number of games you can integrate into Google Classroom with your current Plan.

To integrate as many games as you want in Google Classroom, you need an Academic Plan or a Commercial Plan.

You have exceeded the maximum number of games you can integrate into Microsoft Teams with your current Plan.

To integrate as many games as you want in Microsoft Teams, you need an Academic Plan or a Commercial Plan.

Downloading games is an exclusive feature for users with an Academic Plan or a Commercial Plan.

Get your Academic Plan or your Commercial Plan now and start integrating your games into your LMS, website or blog.

If you wish, you can download a demo game here and test its integration:

bio med and cml treatment

Fill in the Blanks

Played 0

About this activity

bio med and cml treatment

Created by

United Kingdom

Download the paper version to play

Make your own free game from our game creator
Compete against your friends to see who gets the best score in this game

Top Games

%
Anonymous
Anonymous
%
%
%
You have exceeded the maximum number of games you can print with your current Plan.

To print as many games as you want, you need an Academic Plan or a Commercial Plan.

Print your game
bio med and cml treatment
 

Fill in the Blanks

bio med and cml treatmentOnline version

bio med and cml treatment

by paankhuri bhatia
1

Chronic myeloid leukaemia ( CML ) is a myeloproliferative disorder caused by the , which results from formation of the - fusion gene . This gene encodes active , which causes uncontrolled proliferation of cells . The main treatment for CML is biological therapy in the form of ( TKIs ) . The first - line treatment is , a TKI that works by competitively inhibiting the - of the BCR - ABL tyrosine kinase , preventing of downstream signalling and abnormal cell growth . Imatinib is indicated as first - line therapy in , but it may be contraindicated or poorly tolerated in patients with significant , , or due to adverse effects such as or symptoms . In patients who develop or intolerance to Imatinib , second - generation TKIs such as Dasatinib and Nilotinib may be used . Dasatinib is a more TKI that inhibits BCR - ABL as well as SRC family kinases but it is contraindicated in patients at risk of or . Nilotinib is another second - generation TKI that selectively inhibits BCR - ABL tyrosine kinase and may be used as an alternative first - line agent or in Imatinib resistance , although it is contraindicated in patients with or significant disease . Bosutinib is an additional second - generation TKI used in later - line therapy for patients to multiple TKIs , and its use may be limited by and side effects . Ponatinib is a third - generation TKI specifically effective against the T315I mutation of BCR - ABL , which confers resistance to other TKIs , and is indicated in , but it is contraindicated in patients with high risk due to increased risk of . In situations where TKIs are unsuitable , such as , Interferon - ? may be used as a biological therapy , as it works by modulating the immune response and inhibiting myeloid proliferation , although it is less and associated with - like side effects and symptoms .

2

jehbfhksbfks aeifb aifb aibf bjasfkjsfbjksdbf sbfjlsbfls iosfbjslf isbfsbf . s f

3

ekjfbksd sdubfkjsbf ioshfjsbf soiufgsjbfsalfnalsf . . svfjdskbfljsf oiashbfoisbfas oisfboaisfb asjlfaef .

Are you sure you want to leave the page?

If you leave the page, you will lose your game progress.